Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Inks Supply Agreement with Illumina

NEW YORK (GenomeWeb) – Transplant molecular diagnostics company CareDx today announced a supply agreement with Illumina for next-generation sequencing technologies.

Under the terms of the multiyear deal, CareDx's reference and R&D laboratories will have access to Illumina's NGS, microarray equipment, and consumables. Financial and other terms were not disclosed.

CareDx's flagship service is AlloMap Molecular Expression Testing for potential heart transplant rejection. In a statement, the company's President and CEO Peter Maag said that as CareDx expands its product pipeline from the gene expression-based AlloMap to cell-free DNA-based tests, "we believe the technology solutions from Illumina will effectively support our development and commercialization efforts."

Formerly called XDx, CareDx also recently announced the acquisition of transplant firm ImmuMetrix.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.